| Literature DB >> 23633923 |
Rocco Piazza1, Vera Magistroni, Angela Mogavero, Federica Andreoni, Chiara Ambrogio, Roberto Chiarle, Luca Mologni, Petra S Bachmann, Richard B Lock, Paola Collini, Giuseppe Pelosi, Carlo Gambacorti-Passerini.
Abstract
BIM is a proapoptotic member of the Bcl-2 family. Here, we investigated the epigenetic status of the BIM locus in NPM/ALK+ anaplastic large cell lymphoma (ALCL) cell lines and in lymph node biopsies from NPM/ALK+ ALCL patients. We show that BIM is epigenetically silenced in cell lines and lymph node specimens and that treatment with the deacetylase inhibitor trichostatin A restores the histone acetylation, strongly upregulates BIM expression, and induces cell death. BIM silencing occurs through recruitment of MeCP2 and the SIN3a/histone deacetylase 1/2 (HDAC1/2) corepressor complex. This event requires BIM CpG methylation/demethylation with 5-azacytidine that leads to detachment of the MeCP2 corepressor complex and reacetylation of the histone tails. Treatment with the ALK inhibitor PF2341066 or with an inducible shRNA targeting NPM/ALK does not restore BIM locus reacetylation; however, enforced expression of NPM/ALK in an NPM/ALK-negative cell line significantly increases the methylation at the BIM locus. This study demonstrates that BIM is epigenetically silenced in NPM/ALK-positive cells through recruitment of the SIN3a/HDAC1/2 corepressor complex and that NPM/ALK is dispensable to maintain BIM epigenetic silencing but is able to act as an inducer of BIM methylation.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23633923 PMCID: PMC3638354 DOI: 10.1593/neo.121784
Source DB: PubMed Journal: Neoplasia ISSN: 1476-5586 Impact factor: 5.715